Opinion|Videos|September 13, 2023
The Future of R/R B-ALL Treatment
Author(s)Jae Park, MD
Jae Park, MD, wraps up his discussion by highlighting exciting investigational agents on the horizon for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.
The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.
Obesity may increase breast cancer risk partly by removing a natural defense.
Daraxonrasib plus gemcitabine and nab-paclitaxel received FDA breakthrough therapy designation for treatment-naive metastatic pancreatic adenocarcinoma.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Alexandra Leary, MD, PhD, discusses TEDOVA's design, the safety profile of OSE2101, and implications for maintenance in ovarian cancer.
ASCO's first living guideline backs platinum doublets and mirvetuximab soravtansine for FRα+, high-grade platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Drilon on the ARROS-1 Trial Data With Zidesamtinib in ROS1+ NSCLC
2
Dr Rotow on DESTINY-Lung04 Outcomes at WCLC 2026
3
RC148 Plus Chemotherapy in Frontline NSCLC: A Q&A With Yuanyuan Zhao, MD
4
Dr Drilon on How the ARROS-1 Trial May Affect the Current Paradigm in ROS1+ NSCLC
5